<rss version='2.0' >

                    <channel>

                    <title><![CDATA[Protein & Peptide Letters (Volume 33 - Issue 1)]]></title>

                    <link>https://www.benthamscience.com/journal/51</link>

                    <description>

                    RSS Feed for Journals <![CDATA[Protein & Peptide Letters]]> | BenthamScience

                    </description>

                    <generator>EurekaSelect (+https://www.benthamscience.com)</generator>

                    <pubDate>2026-04-01</pubDate>

                    <image>

                    <title><![CDATA[Protein & Peptide Letters (Volume 33 - Issue 1)]]></title>

                    <url></url>

                    <link>https://www.benthamscience.com/journal/51</link>

                    </image><item><title><![CDATA[Creativity, Sustainability, and Education Driving the Future of Protein and Peptide Research]]></title><link>https://www.benthamscience.com/article/154309</link><pubDate>2026-04-01</pubDate><description><![CDATA[]]></description> </item><item><title><![CDATA[Therapeutic Proteins and Peptides of Plant Origin]]></title><link>https://www.benthamscience.com/article/154430</link><pubDate>2026-04-01</pubDate><description><![CDATA[]]></description> </item><item><title><![CDATA[Plant-derived Cyclotides in Immunomodulation and their Therapeutic Potential]]></title><link>https://www.benthamscience.com/article/147248</link><pubDate>2026-04-01</pubDate><description><![CDATA[The incidences of immune-related disorders have drastically increased in recent years across the world population. Treatment and management of these diseases, especially autoimmune disorders, are complex and challenging. Available synthetic drugs are not completely effective and also pose serious side effects for the patients. Cyclotides are a class of plant-derived cyclic peptides (28-37 amino acids) with three conserved disulfide linkages establishing a cyclic cystine knot (CCK) motif that makes them very stable biomolecules. Their inherent stability, bioavailability and membrane-penetrating capabilities render them attractive potential pharmacological agents. Studies have demonstrated that cyclotides can either enhance or suppress immune responses, making them versatile candidates for treating various immune-related disorders. Of more than 1000 cyclotides discovered to date, only up to 15 native cyclotides (e.g. kalata B1, pase and caripe cyclotides) have been screened to demonstrate their immunomodulatory activity. Of special significance is the chemically synthesised lysine mutant of kalata B1 viz. [T20K], where preclinical studies have shown promise in the treatment of the autoimmune disorder, multiple sclerosis. In vivo studies in mice models have demonstrated that daily administration of 1mg/day of [T20K] led to a significant decrease in the level of cytokine secretion, lesser demyelination (<1%) and very low inflammatory index (<0.5), in the immunized mice. Moreover, when compared with other immunosuppressive drugs (azathioprine, prednisolone, and cyclosporine A) there was a notable drop in mortality and morbidity in mice administered with [T20K]. The cyclotides, kalata B1 and MCoTI-I have also been used as scaffolds to graft bioactive peptides with immunomodulatory activity. Subsequent in vitro and in vivo studies of these grafted cyclotides have demonstrated their therapeutic ability. Keeping in view the therapeutic potential of cyclotides as immunomodulatory peptides, the present review discusses its current research scenario and implications for the future in tackling immune-related disorders.]]></description> </item><item><title><![CDATA[Use of Plant Peptidases for the Production of Therapeutic Peptides]]></title><link>https://www.benthamscience.com/article/147631</link><pubDate>2026-04-01</pubDate><description><![CDATA[Peptidases play crucial roles in numerous physiological processes within living organisms. Therefore, they have been employed in various pharmaceutical applications. Plant peptidases have attracted considerable attention in various areas due to their specificity, stability across a diverse range of pH and temperatures, and safety profile. Here, we have focused on the use of plant peptidases, mostly papain and bromelain, to produce biologically active peptides, which confer various health advantages, including antioxidant, antimicrobial, antihypertensive, analgesic, antidiabetic, and anti-inflammatory effects. We have also discussed the importance of the action mechanism of peptidases for generating bioactive peptides with specific sequences and functions, the ecological and sustainability benefits of plant-derived peptidases compared to animal alternatives, digestive stability and bioavailability of peptides, as well as some obstacles to the commercialization of bioactive peptides and key challenges in peptidase-based industrial applications. Finally, we have examined enzyme immobilization as a viable method to enhance the production of bioactive peptides, offering numerous advantages in both research and industry contexts.]]></description> </item><item><title><![CDATA[Effective Plant-Derived Proteins and Peptides in Leukemia Treatment]]></title><link>https://www.benthamscience.com/article/150503</link><pubDate>2026-04-01</pubDate><description><![CDATA[Leukemia is one of the most prevalent malignancies worldwide that causes the unusual evolution of hematopoietic stem cells. The type of leukemia determines the optimal treatment plan and the patient's survival. However, finding safer and more effective medications and developing novel therapeutic strategies are still the most challenging research topics. Nowadays, over half of the medications used to treat cancer are derived from natural ingredients. Medicinal plants are a reliable natural source of anti-leukemic medications. Plant-derived biologically active compounds, including secondary metabolites, have long been considered extremely valuable for treating various human illnesses. However, the limitations of secondary metabolites have led scientists to seek alternative biologically active compounds. Plant-derived proteins and peptides have recently been explored as potential treatments for various human ailments, showing anti-microbial, anti-oxidant, anti-HIV, anti-cancer, ribosome-inactivating, and neuromodulatory properties. Until now, no review article has documented the biologically active proteins and peptides against leukemia. This review article explores the therapeutic properties of plant-derived proteins and peptides against leukemia.]]></description> </item><item><title><![CDATA[Antimicrobial Activity of a Defensin-Rich Fraction from Capsicum chinense Fruits: Insights for Biotechnological Applications against Fungal Infections]]></title><link>https://www.benthamscience.com/article/149479</link><pubDate>2026-04-01</pubDate><description><![CDATA[<p> Background: The increasing resistance of fungal pathogens to conventional antifungal treatments has led to a global rise in fungal infections, affecting human health (Candida spp.) and agricultural productivity (Colletotrichum and Fusarium spp.). Antimicrobial peptides (AMPs), such as defensins, have gained attention for their potential in controlling these infections due to their broad-spectrum activity. </p><p> Objectives: The aim of this study was to partially purify and characterize the antifungal activity of a defensin-enriched fraction (F3) from Capsicum chinense fruits. Specifically, we sought to evaluate its efficacy against pathogenic fungi and yeasts, and to assess the relative abundance of defensins in the fraction.</p><p> Methods: The F3 fraction was obtained using ion exchange and molecular exclusion chromatography. Reverse-phase chromatography (HPLC) was then employed for further purification. The antifungal activity of F3 was tested against Colletotrichum, Fusarium, and Candida species. Mass spectrometry was used to identify and characterize the defensin (CcDef3) within the fraction. The presence of the defensin relative to other components was inferred from electrophoretic profiles and peptide analysis.</p><p> Results: The F3 fraction exhibited significant antifungal activity, with growth inhibition of Colletotrichum lindemuthianum of 51% and 60.9% at concentrations of 100 and 200 μg mL-1, respectively. The fraction also inhibited the growth of several Candida species, notably C. nivariensis (93.8%) and C. bracarensis (79.6%) at 100 μg mL-1. Cell viability analysis indicated a fungistatic effect. Fluorescence microscopy assays showed that F3 induced membrane permeabilization in C. parapsilosis and C. lindemuthianum, and increased ROS production in C. pelliculosa and F. solani. The defensin-rich H8 fraction, containing a 6.5 kDa protein (CcDef3), was identified as a major component via mass spectrometry.</p><p> Discussion: The ongoing development of resistance in fungal strains, particularly Candida species, against traditional antibiotics and antifungals has turned into a significant medical concern and has increased the need for new treatment options.</p><p> Conclusion: These results suggest that the F3 fraction, particularly the defensin CcDef3, has potential as an antifungal agent for biotechnological and therapeutic applications. However, further studies are needed to quantify the contribution of CcDef3 relative to other components in the fraction and to fully isolate the defensin for in-depth analysis.</p>]]></description> </item><item><title><![CDATA[Unravelling Proteomic Pathways: Mechanistic Insights into Schiff Base-Mediated Disruption of Microbial Protein Integrity and Antimicrobial Potential]]></title><link>https://www.benthamscience.com/article/154438</link><pubDate>2026-04-01</pubDate><description><![CDATA[Proteins are essential to the survival and pathogenicity of microorganisms, serving as structural components, enzymes, and regulatory elements. Schiff bases, organic compounds formed by the condensation of primary amines with carbonyl compounds, have emerged as promising antimicrobial agents due to their ability to disrupt microbial protein integrity. This study investigates the multifaceted interactions between Schiff bases and microbial proteins, revealing key mechanistic insights such as membrane disruption, enzyme inhibition, metal chelation, and Reactive Oxygen Species (ROS) generation. Notably, Schiff bases demonstrate potent activity against multidrug-resistant strains, including Staphylococcus aureus, Escherichia coli, and Candida albicans, and exhibit synergistic effects when combined with conventional antibiotics. Proteomic analysis highlights their impact on survival-associated and pathogenicity-related proteins, including chaperones, efflux pumps, and virulence factors. These findings underscore the novelty of targeting microbial proteomes and stress-response pathways, positioning Schiff bases as versatile candidates for next-generation antimicrobial therapies.]]></description> </item><item><title><![CDATA[TRIM44 as a Multifunctional Regulator in Cancer and Non-Cancer Diseases: From Oncogenic Driver to Immune and Stress Response Modulator]]></title><link>https://www.benthamscience.com/article/153789</link><pubDate>2026-04-01</pubDate><description><![CDATA[Tripartite motif-containing protein 44 (TRIM44), a unique member of the TRIM family that lacks the canonical RING domain, has recently attracted significant attention for its broad oncogenic potential across diverse malignancies. Accumulating evidence indicates that TRIM44 is markedly overexpressed in cancers, including colorectal, gastric, lung, breast, ovarian, and prostate carcinomas, as well as glioblastoma, multiple myeloma, and hepatocellular carcinoma. Mechanistically, TRIM44 drives tumor progression by modulating critical signaling pathways, including PI3K/AKT/mTOR, NF-κB, Wnt/β-catenin, and epithelial–mesenchymal transition (EMT), primarily through stabilizing regulatory proteins or participating in non-coding RNA– mediated networks. In addition to its role in cancer, TRIM44 has been implicated in cardiovascular dysfunction, ischemia–reperfusion injury, diabetic complications, and neuroinflammation, underscoring its biological versatility. This review provides an overview of current evidence regarding the multifaceted roles of TRIM44 in both oncogenic and non-oncogenic diseases. By integrating insights from oncology, cardiology, neurology, and metabolic research, this review offers a unified perspective on TRIM44 as a pivotal molecular hub and an emerging diagnostic and therapeutic target.]]></description> </item><item><title><![CDATA[The Dual Nature of Venom: Transforming Toxins into Therapeutic Peptides]]></title><link>https://www.benthamscience.com/article/153250</link><pubDate>2026-04-01</pubDate><description><![CDATA[Venom has been extracted from venomous animals since ancient times for use as hunting tools or biological weapons. In the modern era, the focus has shifted toward the biomedical potential of venom, particularly its rich composition of bioactive compounds. Among these, venom peptides are of particular interest due to their potent and selective biological activities. These peptides often constitute a significant portion of crude venom mixtures and have emerged as promising candidates for drug development. The growing body of research in this field has led to the establishment of “venomics,” a discipline that integrates proteomics, transcriptomics, and genomics to comprehensively characterize venom components. Technological advancements, such as high-throughput sequencing, mass spectrometry, and advanced computational tools, have revolutionized venomics, enabling deeper insights into venom composition, function, and evolutionary biology. These innovations have facilitated the discovery of venom-derived peptides with therapeutic applications, including treatments for chronic pain, cancer, cardiovascular diseases, and autoimmune disorders. However, despite these promising developments, challenges remain. These include the complexity of venom mixtures, ethical considerations in venom collection, and difficulties in translating in vitro findings into clinical applications. This review explores the evolution and technological progress of venomics, highlights key therapeutic applications of venom peptides, and discusses current limitations and future prospects in the field.]]></description> </item><item><title><![CDATA[Recent Development of the Probes for Fluorescence Spectroscopy, Mass Spectrometry and Electron Microscopy in Cancer Diagnosis]]></title><link>https://www.benthamscience.com/article/153798</link><pubDate>2026-04-01</pubDate><description><![CDATA[Among the different types of cancer, brain cancer is one of the most dangerous and fatal. Therefore, the emphasis on effective and accurate diagnosis and treatment methods is highly significant. The combination of fluorescent probes and mass spectrometry has significantly expedited proteomic analysis in brain cancer. The sensitivity and specificity of the fluorescent probes enable simultaneous detection of the biomarkers of brain cancer. The probes show a selective reaction to the enzymes found specifically and different molecular properties that differentiate a glioblastoma from other brain cancers; therefore, a remarkable advancement has occurred. Separately, being a significant advancement, mass spectrometry allows a high level of accuracy towards the identification and analysis of the protein. Additionally, the complete fingerprint of the proteomes is attained. At present, some of the advances made in brain cancer are: activatable fluorescent probes, real-time mass analysis, along with the delivery platform of nanotechnology, which has shown remarkable improvements in tissue uptake with less background interference. Considering some limitations such as tumor heterogeneity, less biological compatibility of probes, as well as some limitations of the blood-brain barrier, collectively these techniques demonstrate an unparalleled advancement in targeted cancer therapy. This article aims to illuminate the principles and recent advancements in fluorescent probe development, along with their synergistic combination with mass spectrometry for the identification and treatment of cancer. The combination of these techniques will completely revolutionize the detection and treatment of brain cancer and will be a turning point in molecular neuro-oncology.]]></description> </item><item><title><![CDATA[Advances in Polymeric Drug Delivery Systems: From Biodegradability to Nanocarrier Technologies]]></title><link>https://www.benthamscience.com/article/154166</link><pubDate>2026-04-01</pubDate><description><![CDATA[Research studies indicate that biodegradable polymers play a crucial role in effective drug delivery, helping to manage drug release and decreasing potential toxic reactions. It thoroughly reviews different types of biodegradable polymers, the ways they are produced, and how they work for releasing drugs. The article begins by outlining drug-delivery polymers and then categorizes them into natural, synthetic, and biodegradable types. Eco-friendliness and biocompatibility are crucial attributes of degradable polymers, enhancing treatment outcomes significantly. The review covers the ways to develop and design biodegradable substances and how they are used in controlled-release medicines. The study delivers detailed descriptions of how controlled drugs are released through diffusion, degradation, and swelling. Different forms of polymer micelles, nanoparticles, dendrimers, and hydrogels are used to assess whether they can boost drug delivery methods. Polymeric nanocarriers improve targeting drugs, ensure their release over a long time, and enhance the solubility of some hydrophobic drugs. They are suitable for use in various types of therapy. The review points out that biodegradable polymers play a role in drug delivery for cancer and ocular disorders. This article aims to examine and evaluate biodegradable polymers, sharing their impacts on the development of controlled-release drug delivery technologies.]]></description> </item><item><title><![CDATA[Targeting Autoimmunity in Myasthenia Gravis: From Conventional to Novel Therapeutic Approaches]]></title><link>https://www.benthamscience.com/article/154124</link><pubDate>2026-04-01</pubDate><description><![CDATA[Myasthenia Gravis is a chronic autoimmune neuromuscular disorder characterized by fluctuating skeletal muscle weakness, most commonly involving ocular, bulbar, respiratory, and limb muscles. This weakness stems from autoantibodies, predominantly immunoglobulin G, against neuromuscular junction components such as acetylcholine receptors or muscle-specific kinase, which ultimately reduces synaptic transmission. MG causes a severe functional impact on normal patients, which often contributes to the reduced quality of life and life-threatening myasthenic crises. This article provides an extensive review of MG’s immunopathogenesis with a focus on T and B lymphocytes, pro-inflammatory cytokine involvement, and the components of the complement cascade. Humoral and innate immune mechanisms cooperate and indirectly result from antibodies and continued neuromuscular dysfunction. Clinical MG approval usually depends on a combination of a clinical approach to testing antibodies, electrophysiological technique trials, and, if necessary, imaging methods for thymoma or thymic fusion abnormalities. Regular MG treatment involves acetylcholinesterase inhibitors, corticosteroids, and steroid-sparing immunosuppressant agents (e.g., azathioprine, mycophenolate mofetil). Rapid treatment of MG exacerbations necessitates a process of rapid immunomodulation, including plasma exchanges and intravenous immunoglobulin to rapidly reduce reversed autoantibodies. Novel drug discovery is aimed at targeted immunomodulation, including clinical application of inhibitors of the complement C5 (eculizumab, ravulizumab, zilucoplan), type I neonatal Fc receptor antagonists (efgartigimod, rozanolixizumab), BTK inhibitors, B-cell-directed monoclonal antibodies, and new dendritic cell T cell antireceptor constructs. They can carve out paradigm shifts as these novel resourcing solutions and therapeutic options allow precision medicine to individual immunopathogenic profiles. Synergistic combinations of conventional and modern medicine are a promising comprehensive strategy for MG patients. Reappraisal driven by the biological mechanism, three may deliver better long-term functional outcomes and quality of life.]]></description> </item><item><title><![CDATA[Bioactive Peptides: Production Strategies, Biological Activities, and Emerging Therapeutic Applications]]></title><link>https://www.benthamscience.com/article/154151</link><pubDate>2026-04-01</pubDate><description><![CDATA[Bioactive peptides, short chains of amino acids derived from natural sources like animals, plants, and marine organisms, are increasingly being explored for their roles in nutrition, functional foods, and therapeutic applications. These peptides display a wide spectrum of biological activities, including antihypertensive, antioxidant, antimicrobial, anti-inflammatory, antidiabetic, and anticancer effects, making them valuable in both disease prevention and treatment. Progress in production techniques such as enzymatic hydrolysis, microbial fermentation, chemical synthesis, and recombinant methods has facilitated the targeted development and efficient production of peptides with specific bioactivities. Techniques such as ultrafiltration, chromatography, mass spectrometry, and electrophoresis are essential for the purification and characterization of particular peptides for bioactivities. Despite their significant potential, challenges like purification difficulties, stability issues, and bioavailability constraints diminish their applicability for widespread use. Advancements in nanocarrier-based drug delivery systems, synthetic biology, and bioinformaticsdriven discovery are overcoming these limitations and expanding therapeutic possibilities. Synergistic multidisciplinary research, the sustainable supply of agro-industrial waste, and enhanced delivery methods will augment the efficacy and commercial viability of bioactive peptides. Current research and development in this field have the potential to advance the creation of next-generation foods and medications that effectively improve global health and well-being. This review uniquely integrates current molecular, biotechnological, and informatics-driven perspectives on bioactive peptide research, offering an updated synthesis of 2024-2025 developments in production strategies, bioassay optimization, and therapeutic translation]]></description> </item><item><title><![CDATA[Recent Applications of Tissue-Engineered 3D Scaffolds in Oncology: Present and Future Perspectives]]></title><link>https://www.benthamscience.com/article/154404</link><pubDate>2026-04-01</pubDate><description><![CDATA[Three-dimensional (3D) scaffolds are essential in tissue engineering, providing optimal conditions for cellular proliferation, tissue repair, and regeneration. In oncology, these structures are crucial for correctly reproducing the in vivo milieu and effectively modelling the tumor microenvironment (TME). Recent advancements indicate that 3D scaffolds are very effective in preserving cell viability, improving connections between tumors and stroma, and properly replicating cellular communication. Developing sophisticated three-dimensional (3D) cell culture methods that accurately emulate the tumor microenvironment (TME) is essential, given the inherent constraints of traditional two-dimensional (2D) cultures and animal models. These advanced 3D in vitro cancer models provide significant advantages for diagnostic and therapeutic applications, improving our understanding of cancer development and therapy. This article examines the latest advancements in three-dimensional tissue scaffolds for cancer therapy. It discusses the potential impact of such shifts on the field and the types of cancer research and treatments that will be feasible in the future.]]></description> </item><item><title><![CDATA[Recent Developments, Challenges in Bitter Gourd Protein and Peptide Extraction Strategies, Techno-Functional Properties, Bioaccessibility, and Commercial Applications]]></title><link>https://www.benthamscience.com/article/154125</link><pubDate>2026-04-01</pubDate><description><![CDATA[<p> Bitter gourd (Momordica charantia L.) has turned out to be a significant source of proteins and bioactive peptides, which have prospects of finding application in functional foods and nutraceuticals. It contains a high level of proteins and phytochemicals, which offer significant health benefits. Leaves, seeds, and stems are also high sources of antioxidants and are good stores of important nutrients. It can help prevent and treat a number of lifestyle-related diseases such as diabetes mellitus, cancer, nephrolithiasis, scabies, abdominal pain, and fever. This review critically evaluates the latest developments in methods of extraction of proteins and peptides from bitter gourd and emphasizes innovative methods. Such methods have enhanced extraction efficiency and protein yield, and improved functional properties. However, there are still issues in optimizing these processes to make them bioavailable and provide stable products. Furthermore, the commercial feasibility of bitter gourd proteins is limited by cost, flexibility, and marketability. This review highlights the need for research to improve extraction methods, explore new uses, and overcome trade barriers. </p>]]></description> </item><item><title><![CDATA[Biocompatible Excipients from Microalgae: Advancing Protein and Peptide Therapeutics through Sustainable Formulation Strategies]]></title><link>https://www.benthamscience.com/article/154405</link><pubDate>2026-04-01</pubDate><description><![CDATA[As a distinctive and sustainable raw material for pharmaceutical excipients, microalgae have emerged as a significant source of biopolymer compounds with immense functional and medicinal value. The pharmacoeconomic importance of key biopolymer compounds isolated from microalgae, such as fucoidan, ulvan, laminarin, and paramylon, having mucoadhesive, bioactive, and controlled release properties that meet the standards of advanced drug delivery systems, has been discussed in this review. Due to the compact cultivation requirements of microalgae that fix significant quantities of carbon dioxide from the environment, biopolymer compounds play an important role in the development of ecologically sustainable production practices. Also critically evaluated in this investigation are the advantages and limitations of industrial-scale cultivation practices of microalgae, which include closed bioreactor cultivation and open-pond cultivation procedures, for biopolymer applications. This study also discusses industrial applications that currently hinder the application of biopolymer compounds of microalgae to the pharmaceutical industry. Moreover, the ability of such compounds to be applied in formulation science has been underscored by their multifaceted properties, from thickening, gelation, and film-forming to immunomodulatory and antioxidant properties. The increased adoption of safer and more ecofriendly alternatives by the pharmaceutical industry to replace synthetic excipients has been facilitated by such compounds’ ability to either complement or replace them. In order to incorporate microalgae-derived excipients into future pharmaceutical formulations, research on such compounds has been underscored as needed]]></description> </item><item><title><![CDATA[Targeting α-Synuclein: Current Strategies and Emerging Therapies for Synucleinopathies]]></title><link>https://www.benthamscience.com/article/154217</link><pubDate>2026-04-01</pubDate><description><![CDATA[<p>Alpha-synuclein (α-syn) is a crucial protein involved in the pathogenesis of Parkinson’s Disease (PD) and other synucleinopathies. It is important with respect to neuron health, regulation of α-syn protein synthesis, and its degradation. Numerous cellular pathways implicated in the process of autophagy, chaperone, and proteolysis play a vital role in the maintenance of α-syn protein homeostasis. Autophagy dysfunction defeats α-syn protein accumulation and neuroinflammation, as present in dementia with Lewy bodies and sporadic PD. Oxidative stress is another key factor that intensifies α-syn protein misfolding and aggregation, thereby leading to neurodegeneration. Involvement in the treatment of α-syn related disorders includes passive and active immunization, inhibitors of protein aggregation, gene silencing technology, modulators of synaptic function, and target drug delivery systems. Other α-syn related therapy approaches include the development of a novel herbal formulation focusing on the gut-brain axis and interventions designed to enhance protein quality control. As clinical trials move forward, minimizing challenges related to the target involved, biomarkers, and patient stratification is crucial to decoding these therapies into effective management. These insights not only advance our understanding of α-syn biology but also highlight the urgency of early and multi-targeted therapeutic interventions.</p>]]></description> </item><item><title><![CDATA[Hybrid 3D Bioprinted Scaffolds for the Delivery of Peptide Therapeutics]]></title><link>https://www.benthamscience.com/article/154442</link><pubDate>2026-04-01</pubDate><description><![CDATA[Protein-based drugs have great potential owing to their high specificity, compatibility, and low toxicity, but they are not widely applicable owing to enzymatic degradation, instability, and poor absorption. Nanostructured hybrid scaffolds comprising bioprinting platforms are a revolutionary approach to confronting such challenges. The combination of natural and artificial polymers with inorganic nanomaterials creates hybrid scaffolds that offer safe environments to improve peptide stability and controlled release. Bioprinting platforms increase spatial accuracy to create personalized drug-delivery platforms with a structure modeled on the extracellular matrix to support complex tissue functions. Recent studies have clarified the therapeutic potential of such platforms. For example, self-assembled peptide hydrogels together with three-dimensional printed polycaprolactone scaffolds have greatly improved osteogenic differentiation and bone regeneration, reflecting their ability to stabilize peptides and support tissue repair. In similar studies, bioinks containing peptides have been used to create extracellular matrix-mimicry environments to improve cell adhesion and proliferation, reflecting their potential to support scaffold-peptide collaborations to improve drugdelivery functions. Aside from the peptide encapsulation approaches, the introduction of techniques such as electrospinning, microfluidics, and extrusion-based printing widens the window of opportunities for the design of hybrid nanoscaffolds that allow customized release profiles while maintaining peptide integrity. Key aspects include peptide-matrix interaction, scaffold degradation kinetics, and their biocompatibility, besides regulatory and translation challenges. Recent emerging directions like AI-guided scaffold design, bio-orthogonal chemistry, and stimuli-responsive nanomaterials also serve to improve prospects toward clinical applications. This review places hybrid bioprinted nanoscaffolds in the perspective of next-generation tools for peptide therapeutics with promising applications in cancer therapy, immunomodulation, and regenerative medicine.]]></description> </item><item><title><![CDATA[Immunity in Harmony: Utilizing Overlapping Epitopes for Tuberculosis and COVID-19 Protection]]></title><link>https://www.benthamscience.com/article/153253</link><pubDate>2026-04-01</pubDate><description><![CDATA[<p>Introduction: The BCG vaccine, widely administered against tuberculosis, has also been linked to reduced incidence of bacterial and viral infections, particularly those affecting the respiratory tract. Its antigens enhance innate immune responses and contribute to therapeutic effects, such as those observed in bladder cancer. Notably, reduced COVID-19 incidence has been reported in BCG-vaccinated populations from TB-endemic regions. </p><p> Methods: To investigate this hypothesis, immunoinformatics tools were employed to identify overlapping CD4, CD8, and B-cell epitopes shared between Mycobacteria and SARS-CoV-2. The most promising CD8 epitope was synthesized using the SPPS-Fmoc method, and antigen-specific Tcell proliferation was evaluated by CFSE dye-dilution assay. Additionally, the expression of proand anti-inflammatory molecules was assessed using qRT-PCR.</p><p> Results: Multiple overlapping T-cell and B-cell epitopes were identified between Mycobacteria and SARS-CoV-2. The T-cell epitopes displayed promiscuous binding characteristics, high immunogenicity, and strong affinity for both HLA class I and class II alleles. Experimental validation using the most immunodominant T-cell epitope confirmed its ability to induce proliferation and differentiation of T cells isolated from COVID-19-vaccinated individuals.</p><p> Discussion: The overlapping T-cell and B-cell epitopes identified through this approach may provide broader and more robust protection than initial exposure to virus-specific antigens, which the immune system encounters for the first time during infection or vaccination. This strategy may therefore support the rapid and effective development of future vaccines, particularly against emerging pathogens.</p><p> Conclusion: The findings suggest that the higher level of protection observed in TB-endemic countries during recent pandemics may be attributable to cross-reactive mycobacterial antigens that stimulate protective immunity.</p>]]></description> </item><item><title><![CDATA[MOTS-c Protects Against Acetaminophen-induced Liver Injury through the MAPK Signaling Pathway]]></title><link>https://www.benthamscience.com/article/153173</link><pubDate>2026-04-01</pubDate><description><![CDATA[<P> Objective: Acetaminophen (APAP)-induced liver injury (AILI) is a leading cause of acute liver failure worldwide, but effective therapeutic strategies are still lacking. MOTS-c, a mitochondrial-derived peptide, has demonstrated hepatoprotective properties in models of nonalcoholic steatohepatitis (NASH) and hepatitis B virus (HBV) infection. This study aims to explore the role and underlying mechanisms of MOTS-c in AILI. </P> <P> Methods: An AILI model was established in male C57BL/6 mice via intraperitoneal (i.p.) injection of APAP (300 mg/kg). The therapeutic potential of MOTS-c and its mechanisms were assessed using behavioral tests, qPCR, western blotting, ELISA, immunohistochemistry, immunofluorescence, and TUNEL staining. </P> <P> Results: MOTS-c levels in both plasma and liver tissues were significantly reduced in APAPinduced AILI mice compared with controls. Administration of MOTS-c via i.p. injection markedly attenuated APAP-induced increases in AST and ALT levels, histopathological liver damage, and other liver injury markers. MOTS-c treatment suppressed the release of pro-inflammatory factors (TNF-α, IL-1β, IL-6, and COX-2) and macrophage infiltration induced by APAP. Furthermore, MOTS-c treatment significantly restored GSH content, diminished reactive oxygen species (ROS) production, and oxidative stress. TUNEL staining confirmed that increased apoptosis in APAPtreated livers was significantly attenuated by MOTS-c, which are key contributors to hepatocyte death and liver injury. Mechanistic studies revealed that MOTS-c inhibited APAP-induced phosphorylation of MAPK pathway components, including ERK, JNK, and p38. The protective effects of MOTS-c on serum ALT and AST levels were abolished by co-treatment with inhibitors of ERK, JNK, and p38. </P> <P> Discussion: This study reveals that the mitochondrial peptide MOTS-c can alleviate drug-induced liver injury by suppressing oxidative stress and inflammation via the MAPK pathway. This positions MOTS-c as a promising therapeutic candidate for treating APAP-induced liver injury. </P> <P> Conclusion: This study demonstrates that administering MOTS-c effectively protects against APAP-induced liver injury in mice. The protective mechanism involves suppressing the damaging MAPK signaling pathway (ERK, JNK, p38), which in turn reduces oxidative stress, inflammation, and cell death.]]></description> </item><item><title><![CDATA[Potent Antioxidant and Antibacterial Activities of ≤3 kDa Hydrolyzed Sarcoplasmic Proteins from IPB-D1 Chicken]]></title><link>https://www.benthamscience.com/article/154167</link><pubDate>2026-04-01</pubDate><description><![CDATA[<p> Introduction: Rising demand for natural bioactive compounds has increased interest in underutilized animal proteins, with sarcoplasmic muscle proteins showing potential for functional peptide production. This study aimed to evaluate the antioxidant and antibacterial activities of sarcoplasmic protein hydrolysates from IPB-D1 chicken, a dual-purpose Indonesian line. </p><p> Methods: Sarcoplasmic proteins were hydrolyzed with chymotrypsin, ultrafiltered (MWCO ≤3 kDa), and analyzed for antioxidant and antibacterial activities. </p><p> Results: Hydrolysates (SHF) showed a sharp decrease in protein concentration (from 49.86 ± 6.19 mg to 0.79 ± 0.05 mg) and disappearance of SDS-PAGE bands, confirming breakdown into smaller peptides. Antioxidant activity increased significantly in SHF compared with the unhydrolyzed fraction (SF). In antibacterial tests, SHF produced larger inhibition zones for all tested bacteria, with the strongest against S. typhi (2.20 ± 1.27 mm) and B. cereus (2.13 ± 0.99 mm), and the lowest against S. aureus (0.36 ± 0.06 mm). Gram-positive bacteria were generally more susceptible than Gram-negative bacteria. </p><p> Discussion: These results suggest that enzymatic hydrolysis and size reduction (<3 kDa) enhance bioactivity by increasing peptide accessibility and interaction with bacterial membranes. The higher sensitivity of Gram-positive strains is likely related to simpler cell wall structures. </p><p> Conclusion: IPB-D1 chicken sarcoplasmic hydrolysates are a promising source of multifunctional peptides with antioxidant and antibacterial activities. This highlights the potential of IPB-D1 not only as a meat source but also as a strategic genetic resource for sustainable bioprocessing and functional food innovation.]]></description> </item><item><title><![CDATA[Peptide Extract from Apricot Kernels Mitigates Damage in Human Aortic Endothelial Cells Induced by Polystyrene Microplastics through the Inhibition of the NLRP3 Signaling Pathway]]></title><link>https://www.benthamscience.com/article/153871</link><pubDate>2026-04-01</pubDate><description><![CDATA[<p> Introduction: Polystyrene microplastics (PS-MPs) contribute to cardiovascular pathologies by inducing vascular endothelial injury through oxidative stress and inflammation. This study aimed to investigate the protective role of apricot kernel peptide extract (AKPE) against PS-MPs- induced damage in human aortic endothelial cells (HAECs) and to elucidate the underlying molecular mechanisms. </p><p> Methods: AKPE was isolated from apricot kernels using an activity-guided fractionation approach based on its protective efficacy in HAECs exposed to PS-MPs. Cytotoxicity and dose-response experiments established an optimal concentration of 20 μM. Subsequent analyses included cell viability (CCK-8 assay), intracellular reactive oxygen species (ROS) and superoxide dismutase (SOD) activity, inflammatory cytokine levels (α, IL-1β, IL-18) via ELISA, apoptosis assessment by flow cytometry, and evaluation of mitochondrial function. Bioactive oligopeptides within AKPE were identified by mass spectrometry. The involvement of the NLRP3 inflammasome and Wnt/β-catenin signaling pathways was examined using Western blotting and quantitative PCR. </p><p> Results: AKPE significantly counteracted the PS-MPs-induced reduction in HAEC viability, increasing it by 16.2% (p < 0.01). It also reduced intracellular ROS levels by 35.1% (p < 0.01) while preserving SOD activity. Furthermore, AKPE suppressed the production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-18) by 17–38% (p < 0.01). PS-MPs-induced mitochondrial dysfunction and apoptosis were markedly attenuated, with a 39.1% decrease in apoptotic cells (p < 0.01). Mass spectrometry identified eight key oligopeptides as the primary bioactive constituents of AKPE. Mechanistically, these components acted synergistically to inhibit NLRP3 inflammasome activation and to modulate the dysregulated Wnt/β-catenin pathway. </p><p> Discussion: AKPE protects HAECs from PS-MPs-induced damage through dual mechanisms: (1) suppressing NLRP3 inflammasome-driven inflammation and (2) mitigating oxidative stress via Wnt/β-catenin pathway inhibition. The synergy among AKPE peptides enhances resilience against PS-MPs, highlighting their potential as natural antioxidants. This study is the first to link apricot kernel peptides to PS-MPs-induced endothelial protection, providing novel insights into combating microplastic-related cardiovascular risks. </p><p> Conclusion: AKPE exerts potent protective effects against oxidative and inflammatory injury in HAECs caused by PS-MPs. These effects are mediated by its constituent bioactive oligopeptides, which concurrently regulate the NLRP3 inflammasome and Wnt/β-catenin signaling pathways. Our findings highlight AKPE's potential as a promising natural therapeutic agent for alleviating vascular endothelial damage associated with microplastic exposure. </p>]]></description> </item><item><title><![CDATA[Proteome-Wide Acetylome Profiling Suggests Extensive Aspirin-Driven Remodeling of Networks Relevant to THP-1 Macrophage Differentiation]]></title><link>https://www.benthamscience.com/article/153144</link><pubDate>2026-04-01</pubDate><description><![CDATA[<p> Introduction: Acetylsalicylic Acid (aspirin or ASA) is known to exhibit immunomodulatory effects not only through Cyclooxygenase (COX) inhibition but also through direct protein acetylation. However, its impact on innate immune cell differentiation remains unclear. </p><p> Materials and Methods: To fill this gap, the study used quantitative acetyl-proteomics to track changes in the lysine acetylome during THP-1 monocyte differentiation into macrophages following ASA preconditioning. </p><p> Results: Our results showed that preconditioning of THP-1 macrophages with 300 μg/ml ASA for 3 hours before differentiation induced persistent acetylation changes. We identified 5,199 differentially acetylated sites across 2,678 proteins, with 2,595 sites upregulated and 2,604 downregulated. The sequence analysis revealed a strong preference of ASA for acidic residues like E_K motifs and hydrophobic regions. The subcellular localization analysis showed notable enrichment in the nucleus (1,166 proteins), cytoplasm (850 proteins), and mitochondria (405 proteins), and frequently contained functional domains like PWWP, SET, RhoGEF, and RNA recognition motifs. </p><p> Discussion: The Gene Ontology analysis linked these proteins to cellular metabolism, regulation, and stimulus response, while our KEGG analysis connected them to neurodegeneration, infection, and metabolic pathways. Furthermore, the protein-protein interaction networks further showed coordinated changes in ribosomal, signaling, and chromatin complexes. </p><p> Conclusion: The findings show that ASA preconditioning leaves a lasting acetylome signature during macrophage differentiation reprogramming regulatory networks relevant to macrophage differentiation and functional networks via motif-directed acetylation. The results provide a plausible COX-independent model in which structural motif-targeted acetylation may underlie ASA’s immunomodulatory role.]]></description> </item><item><title><![CDATA[Irisin Mitigates Myocardial Hypoxia/Reoxygenation Injury by Preserving Mitochondrial Redox Homeostasis via the UCP2-SOD2 Axis]]></title><link>https://www.benthamscience.com/article/153179</link><pubDate>2026-04-01</pubDate><description><![CDATA[<p> Introduction: Mitochondrial redox homeostasis is of utmost significance in myocardial ischemia-reperfusion (I/R) injury. Irisin, a myokine, has drawn extensive attention in research regarding the protection against cardiovascular diseases. </p><p> Methods: This study utilized in vitro Hypoxia/Reoxygenation (H/R) models in H9c2 cardiomyocytes to simulate I/R injury. Cells were pretreated with irisin (20 ng/mL) prior to reoxygenation. UCP2 knockdown was achieved via siRNA/shRNA transfection. Cell viability and apoptosis were assessed using CCK-8 and flow cytometry (Annexin V-FITC/PI staining), respectively. Intracellular calcium dynamics were monitored by Fluo-3/AM confocal imaging, while ROS levels were quantified via DCFH-DA flow cytometry. Key oxidative stress markers (LDH, MDA, GSH-Px, and CAT) and protein expression (ASC, NLRP3, SIRT1, UCP2, and SOD2) were evaluated using commercial kits and Western blotting. Protein interactions were analyzed by coimmunoprecipitation, and ubiquitination levels were measured under proteasomal/lysosomal inhibition (MG132/Leupeptin). </p><p> Results: Irisin attenuated H/R injury in cardiomyocytes by suppressing apoptosis, calcium/ROS overload, and NLRP3 activation through a UCP2-dependent pathway. UCP2 knockdown significantly attenuated irisin’s protection and reduced SOD2 protein stability. Mechanistically, UCP2 bound SOD2 and inhibited its ubiquitin-proteasomal degradation. </p><p> Discussion: This study reveals a novel mechanism where irisin enhances mitochondrial redox homeostasis by promoting UCP2’s function, which stabilizes SOD2 against ubiquitin-proteasomal degradation. This UCP2-SOD2 axis attenuates oxidative stress and inhibits NLRP3 inflammasome activation during cardiac injury, offering a promising dual-targeted therapeutic strategy for I/R injury. </p><p> Conclusion: Irisin protects cardiomyocytes against H/R injury primarily via a novel UCP2-SOD2 axis.]]></description> </item><item><title><![CDATA[Dimerization of SARS-CoV-2 3CLpro and the Role of the A7G/V125G Zipper Interface]]></title><link>https://www.benthamscience.com/article/154159</link><pubDate>2026-04-01</pubDate><description><![CDATA[<p> Introduction/Objectives: The 3-chymotrypsin-like protease (3CLpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for viral replication and is catalytically active only in its dimeric form. Elucidating the molecular determinants that stabilize this dimer may uncover novel antiviral drug targets. This study aimed to characterize the oligomerization behavior of wild-type 3CLpro and to elucidate the functional role of an alanine– valine zipper motif in dimer stability and enzymatic activity. </p><p> Methods: Wild-type 3CLpro (3CLpro-WT) was heterologously expressed in Escherichia coli BL21(DE3) and purified by nickel-affinity chromatography. Oligomerization behavior was examined using Size-Exclusion Chromatography (SEC) under varying protein concentrations, pH conditions, and ionic strengths. An alanine–valine zipper mutant (A7G/V125G; 3CLpro-ZM) was generated by site-directed mutagenesis, overexpressed, purified using the same protocol, and analyzed for changes in folding, oligomerization, and enzymatic activity. </p><p> Results: 3CLpro-WT predominantly existed as a stable dimer, independent of protein concentration and ionic strength, but was destabilized under extreme pH conditions. In contrast, 3CLpro-ZM exhibited a perturbed dimerization equilibrium, altered secondary structure, and a pronounced reduction in both protease and esterase activities compared with the wild-type enzyme. </p><p> Discussion: These findings demonstrate that hydrophobic interactions are the primary force stabilizing the 3CLpro dimer, while ionic interactions provide pH-sensitive modulation. Disruption of the alanine–valine zipper compromises dimer integrity and allosterically impairs catalytic activity, despite the mutation being distant from the active site. </p><p> Conclusion: The Ala7–Val125 interface contributes to 3CLpro stability and activity and may be a promising site for future allosteric inhibitor design.]]></description> </item><item><title><![CDATA[Corrigendum to: A Preliminary Study on the Antibacterial Activity of the Secretion of the Levantine Water Frog, <i>Pelophylax bedriagae</i> (Camerano, 1882) (Anura:Ranidae)]]></title><link>https://www.benthamscience.com/article/152738</link><pubDate>2026-04-01</pubDate><description><![CDATA[<p> After publication, the publisher noted that reference 16 was missing from the text of article [1]. This has now been corrected. </p> <p> The original article can be found online at: https://www.benthamscience.com/article/150920 Details of the error and a correction are provided here. </p> <p> Original: </p> <p> These peptides comprise between 40 and 70 percent hydrophobic amino acids and are abundant in positively charged amino acids, such as histidine, arginine, and lysine [15]. </p> <p> Corrected: </p> <p> These peptides comprise between 40 and 70 percent hydrophobic amino acids and are abundant in positively charged amino acids, such as histidine, arginine, and lysine [15,16].</p>]]></description> </item><item><title><![CDATA[Corrigendum to: Reviewing the Context of Molecular Modeling to Enhance the Application of Machine Learning Technologies for Safer Bioinformatics]]></title><link>https://www.benthamscience.com/article/154109</link><pubDate>2026-04-01</pubDate><description><![CDATA[<p>After publication of this article [1], minor production error is identified, an incorrect link was displayed under Heading 4. This error has now been corrected. </p> <p> The original article can be found online at: https://www.benthamscience.com/article/152908 </p> <p> Details of the errors and the corrections are provided here. </p> <p> Original: </p> <p> When calculating properties related to this function, such as the interaction energy between ligand and receptor in docking, instead of using the entire Cartesian space, the computational effort is substantially reduced since only the grid points are used for these calculations [14]. (https://doi.org/10.1002/jcc.21256). </p> <p> Corrected: </p> <p> When calculating properties related to this function, such as the interaction energy between ligand and receptor in docking, instead of using the entire Cartesian space, the computational effort is substantially reduced since only the grid points are used for these calculations [14].</p>]]></description> </item></channel></rss>